Navigation Links
Omeros Unlocks Orphan GPCRs Linked to Pancreatic Cancer and Cognitive Disorders
Date:3/2/2011

ns linked to orphan GPCRs including cardiovascular disease, asthma, diabetes, pain, obesity, Alzheimer's disease, Parkinson's disease, multiple sclerosis, schizophrenia, learning and cognitive disorders, autism, osteoporosis, osteoarthritis and several forms of cancer.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has six ongoing clinical development programs, including four from its PharmacoSurgery™ platform, the most advanced of which is in a Phase 3 clinical program, and two from its addiction franchise. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, bleeding and central nervous system disorders.

Forward-looking Statements

This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release and include Omeros' expectation that it will unlock a large percentage of the orphan GPCRs, the Company's ability to screen all of the Class A orphan GPCRs by mid-2012, Omeros' expectation that it will soon reach its full screening rate of orphan GPCRs, Omeros' beli
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014  The American ... blood pressure target for people with diabetes and ... or high doses of statins, in keeping with ... enacted by the American College of Cardiology (ACC) ... reflected in the most recent changes to the ...
(Date:12/24/2014)... N.C. , Dec. 23, 2014  Medical Science ... As the key link between the medical device industry ... even more in the coming years as the device ... According to research by benchmarking firm, Best ... can gain an important edge is by harnessing new ...
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) ... Blood Glucose Market" report to their offering. ... market insight focuses on the developments in the self-monitoring ... . Reimbursement analysis and the effects of competitive ... than 73 SMBG meters have been performed, based on ...
Breaking Medicine Technology:New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4Role of Medical Science Liaisons Evolving in Medical Device Sector 2US Self-monitoring Blood Glucose Market 2
... , MORRISTOWN, N.J. , May 24 Watson ... subsidiary, Watson Laboratories, Inc., has received approval from the United States ... for Valacyclovir Hydrochloride tablets, USP, in the 500 and 1000 mg ... to begin shipping the product shortly.   , ...
... Genzyme Corp. has signed a consent decree agreeing to correct manufacturing quality violations at ... government $175 million in unlawful profits from the sale of products that ... , , ... , , ...
Cached Medicine Technology:Watson's Generic VALTREX® 500 mg and 1000 mg Receives FDA Approval 2Watson's Generic VALTREX® 500 mg and 1000 mg Receives FDA Approval 3Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits 2Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits 3
(Date:12/25/2014)... The short film “Color of Honor” by ... of a true 9/11 hero, Welles Remy Crowther. It has ... 24 hours of Nuremberg International Short Film Festival and the ... Actress, screenwriter and director Luciana Lagana plays the mother ... her husband, Gregory Graham - Graham plays a ...
(Date:12/25/2014)... 2014 When head lice hits a home ... frenzy to get rid of it while keeping it from ... Gables now have the solution right in their neighborhood: ... Lice Troopers provides full spectrum head lice screening and treatment ... including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and ...
(Date:12/25/2014)... 2014 (HealthDay News) -- Overeating is common during the holidays, ... moderation, an expert says. "Don,t arrive at a party ... you know you,ll be attending a party, but deprivation leads ... dietitian at Northern Westchester Hospital in Mount Kisco, N.Y., said ... healthy during the day and even to have a snack ...
(Date:12/25/2014)... New York (PRWEB) December 25, 2014 ... continue to move forward in a number of multidistrict ... of West Virginia, Bernstein Liebhard LLP reports. According to ... is scheduled to convene a Joint Status Conference in ... 10:00 a.m. Parties have been directed to submit a ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Each year ... and 2 million hospital admissions across the nation (according ... ). The CDC’s National Hospital Ambulatory Medical Care ... a survey conducted in 2010. They estimated that there ... that resulted in a primary diagnosis of broken bone ...
Breaking Medicine News(10 mins):Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4
... ... season, FORT WORTH, Texas, Nov. 13 ... Jude,during the 2008 holiday shopping season for the 5th anniversary of the,Thanks and ... RadioShack is asking customers to "Give thanks,for the healthy kids in your life, ...
... to emphasize smoking prevention for young girls has been ... Medical School (DMS). The safe, online patient education site ... prevent smoking in young girls 8-11 years old). , ... the siteNo Smoking Room.Org ( www.nosmokingroom.org ) is designed ...
... Nov. 13 NBTY, Inc. (NYSE:,NTY) (http://www.NBTY.com ), ... announced that Arthur Rudolph, its Founder,and a member of ... plan to sell a portion of his NBTY stock ... asset diversification and liquidity. The stock,trading plan was adopted ...
... (Nasdaq: AMLN ) will be presenting at the ... November,19, 2008 at 8:30 a.m. ET. Daniel M. Bradbury, ... providing a corporate overview., The live presentation will ... following the event. The Web cast and recording will ...
... $3.8 million Innovator Award, from the Department of Defense, ... renowned cancer researcher at the University of California, Santa ... is known for his innovative, interdisciplinary research. "This is ... them," said Ruoslahti. "I am very happy at being ...
... Nov. 13 Debiopharm Group,(Debiopharm), a global ... conditions and particularly oncology, today,announced that the ... month formulation,of Trelstar(R) (triptorelin pamoate) has been ... Food and Drug Administration (FDA). Trelstar(R) is ...
Cached Medicine News:Health News:RadioShack Partners With St. Jude Children's Research Hospital(R) on the 5th Anniversary of the Thanks and Giving(R) Campaign 2Health News:RadioShack Partners With St. Jude Children's Research Hospital(R) on the 5th Anniversary of the Thanks and Giving(R) Campaign 3Health News:Innovative new Web site empowers young girls to live smoke-free 2Health News:NBTY Founder Adopts Rule 10b5-1 Trading Plan 2Health News:Cancer researcher receives $3.8 million award from US Department of Defense 2Health News:Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer 2
DCR Set, Angled....
... The Leica CM3050 S Cryostat ... with excellent safety standards for ... applications. The Leica CM3050 S ... for all cryosectioning research applications ...
... The Bright 7500 is a freestanding ... liquid decontamination system and a radial ... to cut a wide range of ... effective for use in high biohazard ...
... - a vision becomes reality. Numerous ... the users many benefits.,The Cryo-Star is ... retraction that incorporates a unique refrigeration ... cooling. This facilitates applications in both ...
Medicine Products: